[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allogeneic-hematopoietic-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allogeneic-hematopoietic-cell-transplantation":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100477806","phase-2-precision-alemtuzumab-dosing-for-allogeneic-hematopoietic-cell-transplantation-100477806",false,"NCT05501756","Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation","Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation in Non-Malignant Diseases","Inclusion Criteria:\n\n* Patients who are undergoing allogeneic HCT at CCHMC with an alemtuzumab-containing preparative regimen for treatment of a non-malignant disease are eligible.\n* For the first 7 patients, patients must have a 10\u002F10 HLA matched related or unrelated stem cell donor, or be receiving a CD34+ selected stem cell product. After the first 7 patients, any donor match may be allowed after data review by the BMT clinicians and the PI.\n\nExclusion Criteria:\n\n* Patients with a history of anaphylaxis to alemtuzumab.\n* Patients who have previously received alemtuzumab and have not cleared alemtuzumab prior to the start of the preparative regimen.\n* Life expectancy less than 4 weeks.\n* Patients receiving dialysis or plasmapheresis at the time of the start of the conditioning regimen.\n* Failure to sign informed consent and\u002For assent, or inability to undergo informed consent process.\n* It is not medically advisable to obtain the specimens necessary for this study.\n* Not able to tolerate subcutaneous dosing (patients with severe skin conditions).\n* Patients with cancer.\n* Patients whose clinical condition suggest there may be inability to successfully perform the PK modeling such as, but not limited to, active flaring of hemophagocytic lymphohistiocytosis in which excessive lymphoproliferation may significantly alter the target-mediated clearance of alemtuzumab and prevent observation of non-target mediated clearance which is needed for robust modeling.\n* Patients whose pre-alemtuzumab level reveals an interfering substance which prevents accurate measurement of alemtuzumab.","ALL",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.15-0.9 ug\u002FmL.",[25],"Allogeneic Hematopoietic Cell Transplantation","RECRUITING","2026-06-10",{"date":29,"type":30},"2026-06-12","ACTUAL",{"date":32,"type":30},"2023-01-11",{"date":34,"type":19},"2028-08-31",{"name":36,"class":37},"Children's Hospital Medical Center, Cincinnati","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":38},"100388020","early-phase-1-study-of-nicotinamide-riboside-supplementation-in-allogeneic-hematopoietic-cell-transplantation-100388020","NCT04332341","Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation","A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.\n* Subject must meet program eligibility criteria\\* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.\n* HLA-identical related donor or unrelated human donor source with bone marrow graft.\n* Subjects must provide a written informed consent.\n\nExclusion Criteria:\n\n* History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide\n* Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.\n* Subjects with uncontrolled intercurrent illness or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.","18 Years",{"count":48,"type":19},20,[50],"EARLY_PHASE1","The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.",[25],"2026-06-04",{"date":55,"type":30},"2026-06-05",{"date":57,"type":30},"2020-05-19",{"date":59,"type":19},"2026-09",{"name":61,"class":37},"Case Comprehensive Cancer Center"]